Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02230592 · ClinicalTrials.gov registry record

PET Imaging of Brain mGluR1 Receptors Using [18F]FIMX

A clinical trial, sponsored by National Institute of Mental Health (NIMH).

Completed
Registry status
19
Enrollment target

NCT02230592 is a clinical trial that has completed, run by National Institute of Mental Health (NIMH). The registered enrollment target is 19 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02230592 has completed, sponsored by National Institute of Mental Health (NIMH).

COMPLETED
Registry status
19 participants
Enrollment target

Study Summary

Objective: Metabotropic glutamate receptors (mGluRs) are G-protein coupled receptors that respond to glutamate by activating proteins inside nerve cells that affect cell metabolism, thereby fine-tuning the signals sent between cells to maintain balance in neuronal activity. mGluR subtype 1 (mGluR1s) are located in several brain regions, including the cerebellum, hippocampus, olfactory bulb, and basal ganglia. mGluR1 activation stimulates phospholipase C, resulting in phosphoinositide hydrolysis and increased intracellular calcium levels. Successful development of a positron emission tomography (PET) ligand to image mGlurR1 would impact clinical management of brain disorders characterized by disruptions in glutamatergic transmission, including anxiety and stress disorders, drug addiction, epilepsy, Huntington s disease, and Parkinson s disease. However, detailed study of mGluR1s has heretofore been hindered by the lack of high affinity and selective ligands for this receptor subtype. The present protocol will evaluate the ability of a new PET ligand, \[18F\]FIMX, to image and quantify mGluR1 in the brain of healthy human volunteers. This protocol covers four phases: 1. Phase 0: screening whole-body scan; 2. Phase 1: kinetic brain imaging to quantify mGluR1 in brain relative to concurrent measurement of the parent radioligand in arterial plasma; 3. Phase 2: if the tracer is successful in Phase 1, we will estimate radiation-absorbed doses of \[18F\]FIMX by performing whole body imaging; 4. Phase 3: test-retest analysis of brain binding relative to concurrent measurement of the parent radioligand in arterial plasma. Study Population: Healthy adult female and male volunteers (n=22, ages 18 to 55) will undergo brain or whole-body imaging.. Design: This study will begin with a screening whole-body scan to confirm that the radioactivity has fairly broad distribution in several organs. For absolute quantification of mGluR1, 22 healthy controls will have brain PET imag

Trial Details

FieldValue
Enrollment Target 19 participants
Start Date 2013-11-08
Est. Completion 2016-06-16

What the Registry Record Tells You About NCT02230592

The ClinicalTrials.gov registry entry for NCT02230592 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Mental Health (NIMH), which has 343 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT02230592 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02230592 about?

NCT02230592 is a clinical study titled "PET Imaging of Brain mGluR1 Receptors Using [18F]FIMX". Objective: Metabotropic glutamate receptors (mGluRs) are G-protein coupled receptors that respond to glutamate by activating proteins inside nerve cells that affect cell metabolism, thereby fine-tuning the signals sent between cells to maintain balance in neuronal activity. mGluR subtype 1 (mGluR1s...

What is the current status of trial NCT02230592?

This trial is currently completed. The enrollment target is 19 participants. The study started on 2013-11-08. Estimated completion is 2016-06-16.

Who is sponsoring clinical trial NCT02230592?

This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.